Lenvaxen is identified for this website as a product containing lenvatinib in 4 mg and 10 mg strengths. The precise manufacturer and regulatory authorization for the Lenvaxen-branded product are not established by the supplied information and therefore require verification before publication.
Lenvatinib is a multi-target receptor tyrosine kinase inhibitor. It acts on signaling receptors involved in angiogenesis, tumor growth and other cellular processes. Important targets include VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR2, FGFR3, FGFR4, PDGFRα, KIT and RET.
Product identity
| Attribute | Information |
|---|---|
| Product | Lenvaxen |
| Generic name | Lenvatinib |
| Active substance | Lenvatinib |
| Stated strengths | 4 mg, 10 mg |
| Dosage form | Taken by mouth once daily. |
| Route | Oral, if the product is a lenvatinib oral capsule |
| Drug class | Receptor tyrosine kinase inhibitor |
| Reference product | LENVIMA |
| Original developer | Eisai |
| Lenvaxen manufacturer | Everest Pharmaceuticals Ltd. |
Lenvatinib and LENVIMA
LENVIMA is the established reference brand for lenvatinib in major markets. Eisai states that lenvatinib was discovered and developed by the company.
Lenvaxen should not be described as LENVIMA unless documentation establishes that relationship. A generic or alternative branded product may contain the same active ingredient while having a different manufacturer, authorization holder, formulation details, packaging and regulatory history.
What does 4 mg or 10 mg mean?
The number of milligrams describes the amount of lenvatinib equivalent contained in the dosage unit. The required daily dose depends on the disease being treated, treatment combination, patient characteristics and regulatory labeling.
Current U.S. labeling identifies 4 mg and 10 mg as the capsule strengths and uses combinations of these strengths to provide several approved daily doses.
Why professional supervision matters
Lenvatinib can affect blood pressure, cardiovascular function, liver and kidney function, protein excretion, thyroid function and other physiological systems. Dose interruptions or reductions may be necessary when significant toxicity occurs.
Patients should therefore use lenvatinib only according to the applicable prescription and official product information.